ENVB: Enveric Biosciences, Inc. Stock

by  •  • Comments Off on ENVB: Enveric Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.11
Enterprise Value ($M) -1.18
Book Value ($M) 3.92
Book Value / Share 1.59
Price / Book 0.79
NCAV ($M) 3.65
NCAV / Share 1.48
Price / NCAV 0.85

Profitability (mra)
Return on Invested Capital (ROIC) -2.37
Return on Assets (ROA) -1.05
Return on Equity (ROE) -1.44

Liquidity (mrq)
Quick Ratio 4.08
Current Ratio 4.08

Balance Sheet (mrq) ($M)
Current Assets 4.83
Assets 5.10
Liabilities 1.18
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -9.63
Net Income -9.57
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -7.73
Cash from Investing 0.00
Cash from Financing 7.67

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-05 13G Intracoastal Capital, Llc 4.99
02-04 13G/A Orca Capital AG 4.90
01-06 13G AdvisorShares Trust 5.90 63.43
11-14 13G/A Armistice Capital, Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 ☐ Transition Report Pursuant to
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2024 ☐ Transition Report Pursuant to Se
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 ☐ Transition Report Pursuan
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 30,394 95,648 31.78
2025-05-14 21,569 145,063 14.87
2025-05-13 10,274 56,711 18.12
2025-05-12 12,062 47,728 25.27

(click for more detail)

Similar Companies
ENSC – Ensysce Biosciences, Inc. ENTO – Entero Therapeutics, Inc.
ENTX – Entera Bio Ltd. EPIX – ESSA Pharma Inc.
EQ – Equillium, Inc.


Financial data and stock pages provided by
Fintel.io